Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 17/20 | 0.60 |
| ▸ | BCL2 | P10415 | 16/20 | 0.60 |
| ▸ | BCL2L1 | Q07817 | 6/20 | 0.55 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21501553 | 0.77 | BCL2 (0.62) | MCL1BCL2BCL2L1BCL2L11 | |
| SCHEMBL2367321 | 0.75 | MCL1 (1.00) | MCL1BCL2BCL2L1 | |
| SCHEMBL2367193 | 0.75 | MCL1 (0.68) | MCL1BCL2BCL2L1BCL2L11 | |
| SCHEMBL14935429 | 0.70 | MCL1 (0.65) | MCL1BCL2BCL2L1 | |
| SCHEMBL29695632 | 0.70 | BCL2 (0.60) | MCL1BCL2BCL2L1BCL2L11 | |
| SCHEMBL2524507 | 0.69 | MCL1 (0.41) | MCL1BCL2BCL2L1 | |
| SCHEMBL14935393 | 0.68 | MCL1 (0.58) | MCL1BCL2BCL2L1 | |
| SCHEMBL2520727 | 0.67 | ALDH1A1 (0.48) | MCL1 | |
| SCHEMBL2528631 | 0.66 | MCL1 (0.51) | MCL1BCL2BCL2L1 | |
| SCHEMBL11346047 | 0.65 | BCL2 (0.60) | MCL1BCL2BCL2L1BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251188-A1 | ACENAPHTHO HETEROCYCLE COMPOUNDS, CYCLODEXTRIN INCLUSION COMPOUNDS AND COMPLEXES, AND USES IN THE MANUFACTURES OF BH3 PROTEIN ANALOGUE, BCL-2 FAMILY PROTEIN INHIBITORS THEREOF | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251188-A1 | ACENAPHTHO HETEROCYCLE COMPOUNDS, CYCLODEXTRIN INCLUSION COMPOUNDS AND COMPLEXES, AND USES IN THE MANUFACTURES OF BH3 PROTEIN ANALOGUE, BCL-2 FAMILY PROTEIN INHIBITORS THEREOF | BID, BCL2, BAX | MCL1 10/4885BCL2 2/4885BCL2L1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.